Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 03, 2023

Docetaxel Plus Carboplatin and Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer: 20-Year Follow-Up

The Oncologist


Additional Info

The Oncologist
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
Oncologist 2023 Nov 02;28(11)e1123-e1126, JL Gomez Marti, A Nasrazadani, Y Ding, D Normolle, AM Brufsky

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading